Logo

BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

Share this

BioXcel's BXCL501 Receives the US FDA's Breakthrough Therapy Designation for Acute Treatment of Agitation Associated with Dementia

Shots:

  • The BTD is based on a P-Ib/II TRANQUILITY study assessing BXCL501 in patients with acute treatment of agitation associated with dementia- including AD
  • The results demonstrated significant reductions in agitation measures @2hrs. post-dose with both 30 and 60 mcg doses as measured by multiple scales. The dose dependent response has the potential to support the company’s plans to evaluate BXCL501 for use across the full range of dementia care settings
  • BXCL501 is an orally dissolving thin film formulation of dexmedetomidine which is a selective alpha-2a receptor agonist for agitation and opioid withdrawal symptoms

 ­ Ref: GlobeNewswire | Image: Linkedin

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions